Cart
sales@molnova.com
Abrilumab
CAS No. 1342290-43-0
Abrilumab( —— )
Catalog No. M36691 CAS No. 1342290-43-0
Abrilumab (MEDI-7183) is a fully human monoclonal antibody against α4β7 that inhibits the α4β7 integrin and can be used to study inflammatory bowel disease and ulcerative colitis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 676 | Get Quote |
|
| 5MG | 1311 | Get Quote |
|
| 10MG | 2119 | Get Quote |
|
| 25MG | 3846 | Get Quote |
|
| 50MG | 5216 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameAbrilumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionAbrilumab (MEDI-7183) is a fully human monoclonal antibody against α4β7 that inhibits the α4β7 integrin and can be used to study inflammatory bowel disease and ulcerative colitis.
-
DescriptionAbrilumab is a fully human monoclonal antibody directed against α4β7. Abrilumab selectively binds the α4β7 integrin heterodimer. Abrilumab can be used for the research of inflammatory bowel disease (IBD).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetIntegrin
-
RecptorIntegrin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1342290-43-0
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Iris Dotan, et al. The role of integrins in the pathogenesis of inflammatory bowel disease: Approved and investigational anti-integrin therapies. Med Res Rev?
molnova catalog
related products
-
Cyclo(RADfK)
Cyclo(RADfK) is a selective α(v)β(3) integrin ligand that has been extensively used for research, therapy, and diagnosis of neoangiogenesis.Cyclo(RADfK) is a negative control for the cyclo (-RGDfK-), the RGD peptide.
-
Cyclo(-RGDfK) TFA
Cyclo(-RGDfK) is a selective αvβ3 integrin inhibitor(IC50 : 0.94 nM).
-
Lifitegrast sodium
Lifitegrast sodium (SAR-1118-023 sodium) is a small molecule integrin antagonist that inhibits T cell-mediated inflammation by blocking the binding of two important cell surface proteins (lymphocyte function-associated antigen 1 and intercellular adhesion molecule 1), which reduces inflammation of the ocular surface, and may be used in the study of dry eye.
